Please assess the completion status of the following clinical trial:

Trial Title: Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Have confirmed laboratory diagnosis of HIV infection~* Presenting with a clinical history of active PML evolving (or continuing to deteriorate) for less than 90 days~* Diagnosis of PML documented for less than 30 days at the inclusion by cerebral imaging (MRI) AND the absence of another demonstrated etiology AND the detection of JCV DNA in the CSF by qualitative PCR.~* Signed written inform consent~Exclusion Criteria:~* Concomitant opportunistic infection of the central nervous system~* Pregnancy, breast-feeding~* Co-infection by the HIV2~* History of immunotherapy including interleukin-2 and alpha-interferon~* History of treatment by FUZEON® or by cidofovir~* Contra-indication to receive FUZEON

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).